EBV B95-8 Strain (Type 1) Purified Virus

Purified virus made from clarified, virus infected tissue culture harvest fluids that are concentrated and cleaned of debris by a combination of ultracentrifugation, ultrafiltration and selection of viral band from a gradient. This preparation contains live virus and can be used to transform primary human lymphocytes.

Virus: Epstein-Barr Virus, B95-8 strain

Virus Preparation: Purified virus

Cell Line for Propagation: B95-8

Suspending Buffer: 10 mM Tris, 150 mM NaCl, 1 mM EDTA, pH 7.5

Virus Particle Count: Varies by lot

Protein Concentration: [varies by lot] mg/mL by Pierce BCA protein method using BSA standard. Alternative methods for determining protein concentration may give different values.

TD₅₀ Titer: [varies by lot] TD₅₀/mL

Transformation Assay: The transformation dose 50 (TD₅₀) of purified EBV B95-8 was performed using gradient separated adult peripheral blood mononuclear cells (PBMCs). The PBMCs were inoculated with 0.2 mL/well log10 dilutions of EBV_B95-8 virus in 4 replicates per dilution and incubated at 37°C for three weeks in RPMI 1640 + 10% FBS. Cultures were refed and examined microscopically for aggregate/clusters of transformed proliferative B-lymphoblast cells and the end-point for transformation read at the end of three weeks by microscopic examination for the presence of transformed clusters of cells. The transformation endpoint was confirmed by intranuclear fluorescent-stained granules with mouse monoclonal antibody to EBNA-1 (ABI Cat. No. 13-156-100) and the TD₅₀/mL calculated using the Karber method.